EIM
CASC

Essex Investment Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Essex Investment Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-153,180
Closed -$567K – 397
2017
Q4 		$567K Buy
+153,180
New +$627K 0.07% 263

Essex Investment Management's CASC Position: Q1 2018 in Review

Essex Investment Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 153,180 shares — an estimated $567K sold.

Essex Investment Management first reported a position in CASC in Q4 2017 and held it in 1 quarter. The position peaked at $567K in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Essex Investment Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Essex Investment Management sold 153,180 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $567K.
  • Essex Investment Management first reported a position in Cascadian Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Essex Investment Management's Cascadian Therapeutics, Inc. position peaked at $567K in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Essex Investment Management's 13F filing for Q1 2018, filed 26 Apr 2018.